This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Drugs » Exenatide

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

EASD: Once a Year Exenatide Introduced at EASD

Posted: Monday, October 08, 2012

Continuous long-term delivery of exenatide with Intarcia's osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability.

A Systematic Review of Newer Drugs for Glucose Control

Posted: Sunday, February 06, 2011

The National Institute for Health and Clinical Excellence (NICE) issued an updated Guideline for newer drugs for the management of all aspects of Type 2 diabetes. The guidelines review the newer agents from four classes with a cost analysis.

For Those 60 Percent of Type 2 Patients Who Are Not in Control

Posted: Saturday, January 29, 2011

Consider a GLP-1 plus a long-acting insulin.

Combining Exenatide with Insulin May Be 'Best Result Ever' for Diabetes Patients

Posted: Tuesday, December 21, 2010

Combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with Type 2 diabetes than insulin alone and helps promote weight loss.

A Once-A-Year Continuous Exenatide Therapy Shows 100% Compliance

Posted: Sunday, October 10, 2010

Implantable device promises diabetes patients continuous exenatide therapy with 100% compliance. Tolerability and weight loss was better with ITCA 650 20 μg/day than with exenatide injections.

EASD: Once-Weekly Exenatide Benefit Sustained over 52 Weeks

Posted: Sunday, October 03, 2010

Once-Weekly Exenatide maintains a drop in A1c of 2 points for more than 52 weeks.

Transdermal GLP-1 Patch for Type 2 Diabetes

Posted: Wednesday, September 29, 2010

TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes.

Switching to Once-Daily Victoza(R) (Liraglutide) from Exenatide Further Improves Blood Sugar Control in Patients with Type 2 Diabetes

Posted: Sunday, April 04, 2010

Diabetes Care has published online the results of the Novo Nordisk (NVO) LEAD™ 6 extension study...

Special Newsflash: Exenatide Once Weekly -- FDA Update

Posted: Tuesday, March 16, 2010

Amylin, Lilly and Alkermes received a Complete Response Letter from FDA for Exenatide Once Weekly. New drug to be called BYDUREON (exenatide for extended-release injectable suspension).

In the complete response letter there are no requests for new pre-clinical or clinical trials. Requests raised in the letter primarily relate to the finalization of the product labeling with accompanying Risk Evaluation and Mitigation Strategy (REMS) and clarification of existing manufacturing processes.

Exenatide Once Weekly DURATION-5 Study Results Announced

Posted: Sunday, December 20, 2009

Eli Lilly and Company, and Amylin announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with Type 2 diabetes.